Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: News
News
News Search  
Nicastrin Mutations Selectively Modulate Notch Processing

17 October 2002. In Alzheimer's disease, the processing of the amyloidβ precursor protein (AβPP) to yield the amyloidogenic Aβ42 peptide is mediated by the intramembrane proteolytic activity of γ-secretase, making this protease a potential target for drug development. One impediment to such a strategy, however, is that the protease is also involved in the processing of notch, a membrane receptor and signal transduction molecule, which, when activated, regulates many intracellular pathways and has a profound impact on cell differentiation.

In yesterday's PNAS online, researchers from the University of Toronto and New York University School of Medicine, report that mutations in the γ-secretase-associated protein, nicastrin, can lead to a selective enhancement of notch processing. This finding suggests that the proteolytic cleavage of AβPP and notch may be independently regulated, and offers hope that specific inhibitors of the AβPP pathway can be developed.

First author Richard Rozmahel, working with Peter St. George-Hyslop and colleagues, discovered the selective activation of notch in presenilin 1 (PS1) null mice that had been crossed with wild-type animals. Presenilin 1 and γ-secretase are considered by many to be one and the same (see related news items 1, 2, and 3). PS1 null mice typically have severe deformities that correlate with a lack of notch processing. However, some of the offspring of the cross had a much milder phenotype and notch processing was increased to about 43 percent that of wild-type levels-notch processing in PS1 nulls is about 34 percent that of wild type. AβPP processing, on the other hand, didn't seem to be affected, as determined by western blotting and ELISA measurements of brain Aβ40 and Aβ42.

The researchers mapped the locus responsible for the rescue to a narrow region of chromosome 1 on some of the wild-type mice. This region contains two strong candidates that could be responsible for the rescue, presenilin 2 and nicastrin. DNA sequence analysis showed that the partially rescued mice hade no changes in the PS2 coding region, nor in PS2 protein levels. The authors did find two missense mutations in the nicastrin gene. One of these (phenylalanine 21 to serine) occurs in the N-terminal hydrophobic region, and could be part of a signal peptide or a membrane-associated domain, the other (isoleucine 678 to threonine) occurs within the transmembrane domain. The authors predict that either of these mutations could subtly alter interactions between nicastrin and other partners in the γ-secretase complex.-Tom Fagan

Reference:
Rozmahel R, Mount HTJ, Chen F, Nguyen V, Huang J, Erdebil S, Liauw J, Yu G, Hasegawa H, Gu YJ, Song Y-Q, Schmidt SD, Nixon RA, Mathews PM, Bergeron C, Fraser P, Westaway D, St. George-Hyslop P. Alleles at the nicastrin locus modify presenilin 1-deficiency phenotype. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14452-7. (Abstract)

 
Comments on News and Primary Papers
  Comment by:  Hui Zheng
Submitted 18 October 2002  |  Permalink Posted 18 October 2002

Using genetic cross-breeding, Rozmahel et al. presented a novel finding that the presenilin 1 (PS1) developmental activity could be modified by genes located on the distal arm of chromosome 1. They further showed that one of the modifiers could be nicastrin, as the polymorphisms between 129 and C57BL/6J strains result in two missense substitutions in the nicastrin protein.
It would be very interesting to see how the two missense substitutions modify the functions of nicastrin and presenilins. Since the PS1 null phenotype does not seem to be affected by genetic background (our unpublished observations), it is likely that the phenotypic differences are caused by differential modification of the PS1 hypomorphic allele used in this study. While the authors clearly show that both the Notch-severe and Notch-mild animals exhibit the same defect in AβPP g-secretase cleavage, the Notch assay and the AβPP assay were done using different tissues (fibroblasts vs. brains) and at different ages (post-natal day 6 versus adult). As embryonic expression of PS1 is a critical factor for its...  Read more

  Comment by:  Michael Wolfe, ARF Advisor
Submitted 24 October 2002  |  Permalink Posted 24 October 2002

The results of this paper are very interesting and emphasize the critical role of nicastrin in PS-dependent γ-secretase activity. The problem is that the genetic findings are interpreted without adequate consideration of the biochemistry of γ-secretase. The principal conclusion is that the γ-secretase cleavage of AβPP and the S3 cleavage of Notch are distinct PS-dependent processes. In the discussion, emphasis is placed on the different sites of cleavage: in the middle of the transmembrane domain for AβPP and near the cytosolic edge for Notch. This apparent difference, however, has been resolved by the recent findings that AβPP is also cleaved near the cytosolic edge and Notch is also cleaved in the middle of their respective transmembrane domains. In other words, the transmembrane domains of these proteins are cleaved at least twice: a γ-secretase cleavage in the middle and an S3 (also called ε) cleavage near the cytosolic edge. These cuts are all PS-dependent. Moreover, in our hands all these cuts occur even after co-immunoprecipitation using PS-specific antibodies from...  Read more
  Submit a Comment on this News Article
Cast your vote and/or make a comment on this news article. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend the Primary Papers

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
ADNI Related Links
ADNI Data at LONI
ADNI Information
DIAN
Foundation for the NIH
AddNeuroMed
neuGRID
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad